Business Context and Reporting Period
Company: MannKind Corporation (MNKD)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: MannKind is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Its lead product candidate is AFREZZA, an ultra-rapid-acting inhaled insulin for the treatment of type 1 and type 2 diabetes. The company also maintains investigational cancer immunotherapy programs (MKC1106-MT) and cancer drug discovery efforts (MKC204).
Key Financial Metrics (Year Ended Dec 31, 2010)
| Metric | Value (in thousands) |
|---|---|
| Revenue | $93 |
| Net Loss | $(170,560) |
| Net Loss Per Share (Basic & Diluted) | $(1.50) |
| Research & Development Expenses | $(112,279) |
| General & Administrative Expenses | $(40,312) |
| Total Operating Expenses | $(152,591) |
| Cash, Cash Equivalents, and Marketable Securities | $70,431 |
| Working Capital | $55,820 |
| Total Assets | $277,256 |
| Total Liabilities | $462,788 |
| Stockholders' Deficit | $(185,532) |
| Senior Convertible Notes Outstanding | $209,335 |
| Note Payable to Related Party (The Mann Group) | $235,319 |
Note: The company has incurred a cumulative net loss of approximately $1.8 billion since inception.
Material Changes vs. Prior Period
- Revenue: Increased from $0 in 2009 to $93,000 in 2010, primarily from license agreements. No product sales were generated.
- Net Loss: Improved from $(220.1) million in 2009 to $(170.6) million in 2010, a 23% reduction in losses.
- Operating Expenses: Total operating expenses decreased by 27% to $152.6 million.
- R&D Expenses: Decreased 28% to $112.3 million due to reduced clinical development costs for AFREZZA and a reduction in force implemented in April 2009. This was partially offset by a $12.8 million loss on disposal of first-generation inhaler assets.
- G&A Expenses: Decreased 25% to $40.3 million due to lower salary costs and non-recurrence of transaction costs related to the Pfizer deal in 2009.
- Debt: Senior convertible notes increased significantly from $112.8 million to $209.3 million following a $100 million offering of 5.75% Senior Convertible Notes due 2015 in August 2010. Borrowings from the related party loan facility increased from $165.0 million to $235.3 million.
- Equity: Stockholders' deficit widened from $(59.2) million to $(185.5) million.
Guidance, Outlook, Risks, and Unusual Items
Regulatory Status and Outlook
On January 18, 2011 (subsequent to the reporting period), the FDA issued a Complete Response Letter regarding the New Drug Application (NDA) for AFREZZA. The FDA requested two additional clinical studies using the next-generation inhaler to bridge data to the Phase 3 trials conducted with the MedTone inhaler. The company plans to conduct these studies (Study 171 and Study 172) to address the agency's requirements.
Restructuring
In February 2011, the company implemented a restructuring to streamline operations and extend its cash runway. This included a workforce reduction of approximately 41% (from 436 to 257 employees) and the halting of certain development programs (MKC253, MKC180, MKC1106-PP). The company expects to record charges of approximately $6.7 million for severance and related benefits.
Liquidity and Capital Resources
As of December 31, 2010, the company had $70.4 million in cash and $98.0 million available under its loan arrangement with The Mann Group. Management believes these resources will fund operations through the fourth quarter of 2011. However, the company explicitly states that if it cannot raise additional capital through equity, debt, or strategic collaborations, there is substantial doubt about its ability to continue as a going concern.
Key Risks
- Regulatory Approval: No assurance that the FDA will accept the proposed clinical study approach or approve AFREZZA.
- Supply Chain: The company terminated its insulin supply agreement with Organon in February 2011. A termination fee of up to $40.1 million may be payable if Organon cannot sell the insulin inventory within 12 months.
- Legal Proceedings: The company is facing securities class action lawsuits and a shareholder derivative suit alleging false statements regarding AFREZZA prospects following the FDA's Complete Response Letter.
- Intellectual Property: Risks of infringement claims regarding pulmonary insulin delivery and cancer vaccines.
Investor Verification Checklist
- FDA Response Plan: Verify the protocols and timelines for the two new clinical studies (171 and 172) requested by the FDA to determine the path to approval.
- Cash Runway: Confirm the company's ability to raise additional capital before the projected end of the fourth quarter of 2011 to avoid insolvency.
- Organon Termination Fee: Monitor the status of the terminated insulin supply agreement to assess the likelihood and timing of the potential $40.1 million termination fee.
- Legal Exposure: Track the progress of the securities class action and derivative lawsuits to estimate potential settlement costs or damages.
- Restructuring Costs: Verify the actual costs incurred for the 41% workforce reduction against the estimated $6.7 million charge.